Real-World Use of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia: A Single-Centre Retrospective Descriptive Analysis
Hamad Almutlaq · 2026
Read Real-World Use of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia: A Single-Centre Retrospective Descriptive Analysis by Hamad Almutlaq (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13510228.txt.
Description
Hamad Almutlaq reviews real-world use of upadacitinib for stubborn eczema at one Saudi hospital. The oral drug blocks a Janus kinase tied to immune overdrive. Middle East clinic data on it remain scarce. Records covered thirty patients treated between 2023 and 2025.
Twenty-eight had follow-up clear enough to judge response. Doctors logged improvement in twenty-seven of those patients. Most responses showed within four weeks of starting. Itch and sleep scores each fell from a median of eight to two. Five patients stopped the drug, two of them over safety or lab worries. Careful picking and close lab watch are the author's advice.
Catalog record
| CREATOR | Hamad Almutlaq |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |